Loading...
PRISM BioLab Co.,LTD
206A.T•JPX
Healthcare
Biotechnology
¥175.00
¥-3.00(-1.69%)
PRISM BioLab Co.,LTD (206A.T) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for PRISM BioLab Co.,LTD (206A.T), featuring income statements, balance sheets, and cash flow data.
Revenue Growth
170.64%
↑ 170.64%
Operating Income Growth
-57.46%
↓ 57.46%
Net Income Growth
-99.18%
↓ 99.18%
Operating Cash Flow Growth
129.22%
↑ 129.22%
Operating Margin
-222.27%
↓ 222.27%
Gross Margin
34.64%
↑ 34.64%
Net Profit Margin
-290.56%
↓ 290.56%
ROE
-39.68%
↓ 39.68%
ROIC
-29.65%
↓ 29.65%
PRISM BioLab Co.,LTD (206A.T) Income Statement & Financial Overview
View the income breakdown for PRISM BioLab Co.,LTD 206A.T across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|
| Revenue | $125.65M | $90.46M | $99.68M |
| Cost of Revenue | $78.12M | $58.19M | $41.80M |
| Gross Profit | $47.53M | $32.27M | $57.88M |
| Gross Profit Ratio | $0.38 | $0.36 | $0.58 |
| R&D Expenses | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $283.59M | $271.54M | $266.67M |
| Operating Expenses | $283.59M | $271.54M | $266.67M |
| Total Costs & Expenses | -$361.71M | -$329.73M | $308.47M |
| Interest Income | $190000.00 | $344000.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $0.00 | -$24.39M |
| EBITDA | -$190.89M | -$479.56M | -$233.19M |
| EBITDA Ratio | -$1.52 | -$5.30 | -$2.34 |
| Operating Income | -$236.06M | -$239.26M | -$208.80M |
| Operating Income Ratio | -$1.88 | -$2.64 | -$2.09 |
| Other Income/Expenses (Net) | $45.17M | -$240.30M | -$24.39M |
| Income Before Tax | -$190.89M | -$479.56M | -$233.19M |
| Income Before Tax Ratio | -$1.52 | -$5.30 | -$2.34 |
| Income Tax Expense | $605000.00 | $403000.00 | $303000.00 |
| Net Income | -$191.49M | -$479.97M | -$233.49M |
| Net Income Ratio | -$1.52 | -$5.31 | -$2.34 |
| EPS | -$5.30 | -$13.42 | -$7.45 |
| Diluted EPS | -$5.30 | -$13.42 | -$7.45 |
| Weighted Avg Shares Outstanding | $36.10M | $35.77M | $31.35M |
| Weighted Avg Shares Outstanding (Diluted) | $36.10M | $35.77M | $31.35M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan